Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector

Sort by: Date|Relevance

Disruptive Technology Poised to Deliver Significant Advancement in Bladder Cancer Detection

Chris Temple, editor and publisher of The National Investor, explains why he recommends this small-cap as a Buy. Imagin Medical's disruptive technology is poised to deliver the most significant advancement in bladder cancer detection and removal in decades , ma...

Here Be Dragons, 'Hic Sunt Dracones'

We have sailed off the map of the known world into totally uncharted waters. No one, including me, knows exactly where we are or where we are headed. But hic sunt dracones is an excellent warning, here be dragons. If I was still flying and needed to give a brief to my...

The Seed-to-Sale Cannabis Co. Offering Real Growth Value & Opportunity

Stockhouse investors are likely familiar with one of the most recognizable names in the Canadian retail cannabis space – Delta 9 Cannabis Inc . (DN) ( TSX.DN , OTCQB: DLTNF , Forum ). But the company is much more than just stores. Delta 9 is a fully vertically-integrat...

A psychedelic renaissance

Fifty-three years after LSD was banned by the FDA, psychedelic drugs are making a comeback. Only instead of being the pills, mushrooms and acid tabs that helped college students to “turn on, tune in, drop out” Timothy Leary-style, today’...

Why These 2 Investment Professionals Say This Telemedicine Company Is One of Their Top Picks

As the coronavirus pandemic has accelerated the move to telemedicine, two investment professionals are following CloudMD, a small cap rapidly expanding in Canada. As people are avoiding going to doctor's offices and hospitals during the coronavirus pandemic,...

CloudMD Is My TeleHealth Stock

An entirely new—and highly profitable—industry is being borne out in 2020— TeleHealth. CloudMD Software & Services Inc. (DOC:CSE; DOCRF:OTCQB; 6PH:FSE) is my favorite way to play teleHealth. It's growing quickly with over 100,000 patients registered on its ap...

Forging a New Path into the Medical Cannabis Space

Although 2019 was in many ways ‘The Year that the Cannabis Sector Would Like to Forget’, there are many pioneering ways that a company can take to generate revenue in the still-emerging medical cannabis and CBD markets. One such company has been advancing st...

Royalties Face Mine Problems and Tax Bills

Royal Gold Inc. (RGLD:NASDAQ; RGL:TSX, US$115.82) (115.82) is facing uncertainty on its main asset, the Mount Milligan copper-gold mine in British Columbia, whose stream accounts for nearly 30% of the company's revenue and its book value. The mine has experienced lower...

Blacktop politics

Benjamin Franklin once said; “Out of adversity comes opportunity.” The adversity the United States now faces with the coronavirus pandemic is the worst national emergency the country has faced since World War II, more serious, far more deadly, than a...

XPhyto: The Cutting Edge of Medical Cannabis Science

At the forefront of the next wave of cannabis commercialization, is a German-focused company with headquarters in Vancouver, XPhyto Therapeutics Corp. (CSE: XPHY; FSE: 4XT) , that is building a much-coveted cannabis R&D cultivation facility in a converted nuclear bunker and o...
1 2 3 4 5 6 7 8 9 10 ...